ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage
clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced
today that Steve Shallcross, the Company's Chief Financial Officer, has been named interim CEO to
succeed Jeff Riley, who has resigned as an officer and director of the Company, effective
immediately, for personal reasons.
Jeffrey Kraws, the Company's non-executive Independent Chairman of the Board stated, "The Board
is very confident in the ability of Steve Shallcross and Joe
Sliman, the Company's Chief Medical Officer, to continue the Company's development activities. We understand Jeff's
decision to step down as CEO and as a Board member and are grateful for his leadership and accomplishments. During his tenure, he
has led significant changes at the Company, including its transition to a company focused on therapeutics that preserve the
microbiome. On behalf of the Board and the Company, we thank Jeff for his dedication and many years of service, and wish him all
the best in his future endeavors."
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics designed to preserve
the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are:
(1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous
(IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the
emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing
organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company
is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel
discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
This press release includes forward-looking statements on Synthetic Biologics' current expectations and projections about
future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are
based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which
are difficult to predict and include statements regarding the intended benefits of its drug candidates. These forward-looking
statements are based on management's expectations and assumptions as of the date of this press release and are subject to a
number of substantial risks and uncertainties, many of which are difficult to predict and could cause actual results to differ
materially and adversely from current expectations and assumptions from those set forth, projected or implied by any
forward-looking statements. Important factors that could cause actual results to differ materially from current expectations
include, among others, Synthetic Biologics' ability to retain a new CEO that successfully integrates with its management team,
Synthetic Biologics' product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior
results, Synthetic Biologics' ability to initiate clinical trials and if initiated, to complete them on time and achieve desired
results and benefits, Synthetic Biologics' clinical trials continuing enrollment as expected, Synthetic Biologics' ability to
obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to Synthetic Biologics' ability to promote or commercialize its product candidates for specific
indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of
Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive, Synthetic
Biologics' ability to maintain its license agreements, the continued maintenance and growth of Synthetic Biologics' patent
estate, Synthetic Biologics becoming and remaining profitable, Synthetic Biologics' ability to establish and maintain
collaborations, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and
development activities, a loss of any of Synthetic Biologics' key scientists or management personnel, and other factors described
in Synthetic Biologics' Annual Report on Form 10-K for the year ended December 31, 2016, and its
other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is
provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to revise or update any
forward-looking statements contained in this release on account of new information, future events, or otherwise, except as
required by law.
View original content with multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-announces-management-changes-300566535.html
SOURCE Synthetic Biologics, Inc.